Amplifier Therapeutics is a biotechnology company focused on developing treatments for diseases related to aging, such as metabolic and cardiovascular conditions. Their main approach involves activating AMP-activated protein kinase (AMPK), a key regulator of cellular energy that tends to decline with age. By targeting AMPK, they aim to address various health issues associated with aging. In October 2023, the company began a Phase 1B clinical trial in the European Union to test ATX-304, their lead AMPK activator, in prediabetic, overweight, or obese individuals.